Press Releases


Consortium agreement in Huntington's disease worth circa £0.9 million

IXICO plc, the neuroimaging Contract Research Organisation (CRO) delivering advanced AI analytical insights in neuroscience, is pleased to announce it has entered a multi-party consortium for the development of improved imaging biomarkers for the early detection and staging of Huntington's disease ('HD').

Read more

Contract award with a new client for a Huntington's Disease ('HD') trial worth circa £800,000

IXICO plc, the neuroimaging Contract Research Organisation (CRO) delivering advanced AI analytical insights in neuroscience, is pleased to announce it has been selected by a new client to support its global prospective observational study to assess participants for the early detection of HD.

Read more

Contract awarded for Phase 1b/2 Huntington's disease trial worth circa £800k

Reflection on IXICO's ability and expertise within the Huntington's disease trials space IXICO plc, the medical imaging advanced analytics company delivering intelligent insights in neuroscience announces that it has been selected by an existing US biotech client to provide PET and MRI neuroimaging services for an open-label Phase I/II dose finding study.

Read more

IXICO Hails The Introduction of IXIQ.Ai, Its New Brain Imaging Technology

The new platform has been developed and validated in collaboration with academic and pharma partners, the company said. IXICO said its next-generation brain imaging technology that is more sensitive, accurate and flexible than the current platform will be available for clinical trials from next month (March).

Read more

Appointment of Senior Therapeutic Advisor

Leading International Clinical trial expert, Dr. Lynne Hughes, appointed as Advisor to the Company. IXICO plc, the medical imaging advanced analytics company delivering intelligent insights in neuroscience, announces that it has appointed Dr. Lynne Hughes, an international neurology clinical trial research expert, to IXICO as a Senior Therapeutic Advisor to the Company. Dr.

Read more

Engagement In Big Data Research Dementia Collaboration

IXICO continues its engagement in Dementias Platform UK as it enters its second phase IXICO plc (AIM: IXI), the data analytics company delivering insights in neuroscience, announces that it has extended its commitment to Dementias Platform UK (DPUK) as it enters its second phase.

Read more

Non-Executive Director Appointment

IXICO plc, the data analytics company delivering insights in neuroscience, is pleased to announce the appointment of Kate Rogers as a Non-Executive Director and Chair of the Audit Committee with effect from 21 January 2022.

Read more

Huntington's Disease Contract Update

IXICO plc, the data analytics company delivering insights in neuroscience, announces a further update to the Huntington's disease Phase III contract. As previously announced on 23 March 2021, the client decided to stop dosing participants in its Phase III trial in Huntington's disease following a pre-planned review of the data.

Read more

1-8 of 63 results